Möchten Sie immer auf dem neuesten Stand bleiben?

- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis - -...

Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Wealth Management Platform - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Wealth...

Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Cognitive Assessment & Training for Alzheimer's Disease Market by Offering Type, Delivery Mode, Technology Platform, Supervision Level, Disease...

Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Digital Biomarkers Market by Type, Therapy, Application, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.The...

– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results – –...

NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) -- WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD; HKEX: 0800), a global leader in autonomous driving technology, today announced its unaudited...

FY 2025/26 results in line with preliminary figures released on 16 April: Record commercial performance, challenging execution on some rolling stock contracts, cash in line with guidance Record order...

Trading update for the first three months of 2026 Sales in line with expectations Financial highlights Stable Q1 2026 like-for-like sales1 and total consolidated sales of €917 million (-7% vs Q1...

INTERIM REPORT OF MARIMEKKO, Q1 2026: Marimekko’s net sales and operating profit in the first quarter grew despite the continued challenging market situati

(Bergen, 13 May 2026) Mowi had its second best first quarter ever with operational profit of EUR 221 million on seasonally record-high revenues of 1.54 billion. Mowi began 2026 with more new records;...